BioCardia Q2 net loss narrows on lower R&D costs - BCDA News | RalliesBioCardia Q2 net loss narrows on lower R&D costs
B
BCDA• Quarterly results
- Cellular therapeutics developer's Q2 net loss narrowed year over year on lower R&D expenses.
- Company ended Q2 with $4.1 million in cash after raising $4.9 million during the quarter.
- Q2 R&D expenses fell as the CardiAMP HF trial closed out, offset by new trial and regulatory work.
| Metric | Actual |
|---|
| Q2 Net Loss | $1.61 million |
| Q2 Loss Per Basic Share | $0.13 |
| Q2 Operating Income | -$1.62 million |
Outlook and development plans
- BioCardia plans CardiAMP Cell Therapy regulatory submission to Japan PMDA in Q4 2026.
- Company continues CardiAMP Cell Therapy development in the U.S. with ongoing FDA engagement.
- BioCardia is pursuing strategic partnerships and licensing for Helix/Heart3D and its allogeneic MSC platform.
Analyst coverage and valuation
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no or .
"sell"
"strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy".Wall Street's median 12-month price target for BioCardia Inc is $15.50, about 1,562.9% above its August 11 closing price of $0.93.
